Day: March 23, 2021
VANCOUVER, British Columbia, March 23, 2021 (GLOBE NEWSWIRE) — A.I.S. Resources Limited (TSX: AIS, OTCQB: AISSF) (the “Company” or “AIS”) is delighted to report that AIS Resources has acquired from Tech One Lithium Resources Corp. a 20% interest in Mining Licence File Number 23262 (Candela II) covering 3 sq km on the Incahuasi Salar in the lithium triangle in Argentina. The Candela II licence neighbours Gangfeng Lithium, China’s largest producer of the battery metal and Orocobre, a lithium producer in Argentina. Tech One Lithium Resources Corporation (“Tech One”), a private company, has optioned the Exploration license for 12 months to complete due diligence and further exploration work, and has the right to acquire 100% of the property for USD one million dollars (CAD1.3 million). The option fee paid by...
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
Written by Customer Service on . Posted in Public Companies.
NEW YORK, March 23, 2021 (GLOBE NEWSWIRE) — Cipla Therapeutics, a division of Cipla USA Inc., an affiliate of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; referred to as “Cipla”) and SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats.
The World Health Organization has declared that anti-microbial resistance (AMR) one of the top 10 global public health threats facing humanity2 which puts at risk the effective prevention and treatment of a wide range of infections. According to the AMR Industry Alliance, a global AMR private sector coalition, AMR is the ability of a microorganism (such as bacteria,...
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431
Written by Customer Service on . Posted in Public Companies.
EDISON, N.J., March 23, 2021 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) – driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced positive results from an in vivo study of CRV431 in a Diet-Induced Animal Model Of Non-alcoholic fatty liver Disease (“DIAMOND”).1
It is estimated by the National Institutes of Health, that between 3% – 12% of the U.S. adult population has NASH.2 There are currently at least 90 drug candidates targeting NASH in various stages of development.3 The majority of these drug candidates are designed to target metabolic perturbations leading to the pathogenesis of NASH and thereby seek to normalize glycemic control,...
FAX Capital Closes Acquisition of Carson Dunlop and Appoints Graham Badun as CEO of New Platform Company
Written by Customer Service on . Posted in Mergers And Acquisitions.
NOT FOR DISSEMINATION IN THE UNITED STATES OR DISTRIBUTION TO U.S. NEWS WIRE SERVICES
TORONTO, March 23, 2021 (GLOBE NEWSWIRE) — FAX Capital Corp. (the “Company” or “FAX Capital”) (TSX: FXC and FXC.WT) today announced that it has, through its wholly owned subsidiary, completed its previously announced $11.75M acquisition of an approximate 78 per cent controlling interest in Carson, Dunlop & Associates Ltd. (“Carson Dunlop”). The acquisition was financed through the Company’s available cash balance (all currency figures are in Canadian dollars).
FAX Capital also announced today that it has appointed Graham Badun as Chief Executive Officer of its new platform company, which will leverage Carson Dunlop as its foundational asset as it focuses on organic growth initiatives and acquisition opportunities of complementary businesses...
Gene Therapy Market Size 2021 | To Exhibit 33.6% CAGR and Hit USD 35.67 billion by 2027
Written by Customer Service on . Posted in Mergers And Acquisitions.
Pune, India, March 23, 2021 (GLOBE NEWSWIRE) — The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help in treating cancer in those patients who are at high risks of getting affected by this disease through genetic mutations.
“The report further mentions that the market size was USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period”
The U.S. to Dominate Owing to Presence of Favorable Policies
In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions....
Proposed Amendment to the Principal Amount of the Affected Securities Meeting of the Etp Securityholders
Written by Customer Service on . Posted in Public Companies.
23 March 2021
LEI: 2138003QW2ZAYZODBU23
LSE Code: QQQS
WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland)WISDOMTREE NASDAQ 100® 3X DAILY SHORT SECURITIESISIN:IE00BLRPRJ20
PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIESMEETING OF THE ETP SECURITYHOLDERS
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent financial adviser.
NOTICE is hereby given that, pursuant to the provisions of the trust deed dated 30 November 2012 (as amended) constituting (inter alia) the WisdomTree NASDAQ 100® 3x Daily Short Securities (the “Affected Securities”) and made between (1) WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”), (2) The...
Offentliggørelse af indre værdi
Written by Customer Service on . Posted in Public Companies.
På grund af tekniske vanskeligheder er det p.t. ikke muligt at offentliggøre indre værdier via de almindelige distributionskanaler. De offentliggøres derfor på denne vis, indtil de tekniske problemer er løst
Indre værdi er oplyst i skema nedenfor indeholdende oversigt over samtlige foreninger og afdelinger under vores administration.
Eventuelle henvendelser vedrørende denne meddelelse kan rettes til undertegnede på telefon 3814 6600.
Med venlig hilsenInvest Administration A/S
Niels Erik Eberhard
DirektørOMX Short Name
Navn
ISIN
Indre VærdiInvesteringsforeningen Gudme Raaschou
GRIEHY
European High Yield
DK0016205255
113,03GRIUSHY
US High Yield
DK0060477859
100,57GRIEMA
Emerging Markets Aktier
DK0060184083
118,52GRIEMD
Emerging Markets Debt
DK0060260602
87,27GRIEJD
Europæiske Ejendomsaktier
DK0061133899
105,83Investeringsforeningen...
Frontier Announces Launch of Initial Public Offering
Written by Customer Service on . Posted in Public Companies.
DENVER, March 23, 2021 (GLOBE NEWSWIRE) — Frontier Group Holdings, Inc. (“Frontier”) today announced the launch of its initial public offering of 30 million shares of its common stock. The offering consists of 15 million shares of common stock offered by Frontier and 15 million shares of common stock to be sold by certain of Frontier’s existing stockholders. Frontier will not receive any proceeds from the sale of the shares by the selling stockholders. A selling stockholder intends to grant the underwriters a 30-day option to buy an additional 4.5 million shares of common stock from such selling stockholder at the initial public offering price, less the underwriting discount and commissions. The initial public offering price is currently expected to be between $19 and $21 per share. Frontier intends to list its common stock on the...
Liquidia Corporation Reports Full-Year 2020 Financial Results and Provides Corporate Update
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
– Integrated RareGen (now known as Liquidia PAH) to establish commercial presence in PAH– Clarified path towards submitting response to CRL for LIQ861 in mid-2021– Reducing net annual spending more than 40% in 2021 compared to 2020 cash burn– Company to host webcast and conference call today at 8:30 a.m. ET
RESEARCH TRIANGLE PARK, N.C., March 23, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the full-year ended December 31, 2020. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the 2020 financial results and provide a corporate update.
Damian deGoa, Liquidia’s Chief Executive Officer, said: “Activity level has been high. We closed the acquisition and integration of RareGen, LLC, now known as...
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Anti-pTau Alzheimer’s vaccine delivers potent immunogenicity in ongoing Phase 1b/2a study, supporting further development into Phase 2/3Anti-Abeta Alzheimer’s vaccine advancing based on Phase 1b safety and immunogenicity results in Down syndrome; further interim results expected in Q2 for Phase 2 in Alzheimer’s disease
Morphomer™ Tau aggregation inhibitor achieves target brain exposure in Phase 1; program advancing in NeuroOrphan indications and Alzheimer’s disease
First-in-class alpha-synuclein PET diagnostic to report clinical results in Q3 2021
Advancing multiple candidates targeting the NLRP3 inflammasome pathway for CNS and non-CNS indications
Ongoing strong financial position of CHF 225.9 million in cash ensures the Company is fully financed through Q1 2024, excluding potential incoming milestonesLAUSANNE, Switzerland, March...